The UK life sciences sector is set to benefit from the UK’s first national total-body PET imaging platform for drug discovery. The National PET Imaging Platform (NPIP), which is the result of a partnership between Medicines Discovery Catapult (MDC), the Medical Research Council (MRC) and Innovate UK, is designed to enhance the scope of research into multi-organ, complex diseases using two PET/CT imaging scanners from Siemens Healthineers.
NPIP's advanced total-body PET technology, funded by a £32 million investment from the UK Government through UK Research and Innovation (UKRI), will help drive the UK's scientific reputation on a global stage. Equipped with technical precision that redefines the boundaries of molecular imaging and optimises operational performance, Biograph Vision Quadra PET/CT scanners from Siemens Healthineers enable imaging of a patient's entire body in near real-time. The programme is set to transform the quality of medical research and care across the UK.
"Total-body PET scanning isn't just a leap in technology, it's a giant stride towards a healthier future,” states Lawrence Foulsham, Business Manager for Molecular Imaging at Siemens Healthineers GB&I. “The NPIP launch is a testament to our commitment to innovation and collaboration in the field of medical imaging. We at Siemens Healthineers are incredibly proud to support this initiative with two Biograph Vision Quadra PET/CT scanners which are set to support NPIP in unlocking a range of clinical and research opportunities across the country."
Read more about the programme here.
